Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. AGC Inc.
  6. News
  7. Summary
    5201   JP3112000009


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AGC : Biologics' Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

06/07/2021 | 10:03pm EDT

AGC (Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that its biopharmaceutical CDMO subsidiary, AGC Biologics (Headquarters: United States), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC's Heidelberg, Germany facility.

'We are honored that BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,' says AGC Biologics Chief Business Officer, Mark Womack. 'We are very proud of our efforts to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the COVID-19 pandemic.'

AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech's mRNA-based vaccine manufacturing process.

'The team at Heidelberg is enthusiastically embracing this important project with BioNTech,' says AGC Biologics General Manager, Heidelberg, Dieter Kramer. 'Every team member has a deep sense of pride in our COVID-19 teams and we look forward to supporting BioNTech in the production of their mRNA-based COVID-19 vaccine with Plasmid DNA.'

AGC Biologics' Heidelberg facility has over 20 years of experience delivering a very wide range of microbial programs for our customers. In addition, the site is AGC's Center of Excellence for Plasmid DNA (pDNA) production, as part of their end-to-end Cell and Gene Therapy offering.

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,700 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients' most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit .


AGC - Asahi Glass Co. Ltd. published this content on 08 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2021 02:02:01 UTC.

© Publicnow 2021
All news about AGC INC.
07/14AGC : to Revise Pricing for Architectural Glass Products in Japan
07/01AGC : Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S...
06/29AGC INC. : Ex-dividend day for interim dividend
06/24AGC : Opening Ceremony Held at AGC Yokohama Technical Center
06/23AGC : Photovoltaics-embedded Glass SunjouleTM Adopted at Global Zero Emission Re..
06/15Nikkei inches down as chip shares track U.S. peers; Toyota lifts Topix
06/15AGC : Notice regarding Transfer of Architectural Glass Business in North America
06/15Cardinal Glass Industries, Inc. entered into an agreement to acquire North Am..
06/07AGC : Biologics' Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 ..
06/07AGC : Niigata University and AGC Commence Industry-Academia Collaboration to Imp..
More news
Sales 2021 1 642 B 14 972 M 14 972 M
Net income 2021 94 936 M 866 M 866 M
Net Debt 2021 554 B 5 052 M 5 052 M
P/E ratio 2021 10,9x
Yield 2021 2,94%
Capitalization 1 033 B 9 408 M 9 414 M
EV / Sales 2021 0,97x
EV / Sales 2022 0,93x
Nbr of Employees 56 179
Free-Float 87,7%
Chart AGC INC.
Duration : Period :
AGC Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGC INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 4 665,00 JPY
Average target price 5 755,00 JPY
Spread / Average Target 23,4%
EPS Revisions
Managers and Directors
Takuya Shimamura President, CEO & Representative Director
Shinji Miyaji CFO, Representative Director & Executive VP
Yoshinori Hirai Director, CTO & Senior Managing Executive Officer
Yasuchika Hasegawa Independent Outside Director
Hiroyuki Yanagi Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
AGC INC.29.58%9 408
SAINT-GOBAIN60.67%37 203
ASSA ABLOY AB37.48%36 175